VEGF和bFGF是最重要的促血管和淋巴管新生促进因子。资料显示VEGF和bFGF在血管生成方面有协同促进作用，但很少见相关进一步的协同靶向抑制肿瘤血管新生的报道。我们率先构建了VEGF/bFGF复合肽，它既可作为疫苗刺激机体同时产生抗VEGF和抗bFGF中和抗体而靶向抗肿瘤血管新生，又能以自身表位肽成分竞争结合受体而作为小分子抑制剂直接抑制肿瘤生长的双重作用。前期工作已经初步证明其在抑制肿瘤生长中的作用。本项目将进一步开展VEGF/bFGF复合肽的靶向协同抑制肿瘤血管和淋巴管新生、抑制肿瘤生长和转移的作用及其发挥作用的相关机制，明确VEGF/bFGF复合肽的免疫应答机制，进而揭示该复合肽诱导产生的抗VEGF和抗bFGF抗体协同靶向抑制肿瘤血管和淋巴管新生中的分子机制，以及它对克服单一因子抗体或多肽疫苗耐药作用的效果与机制，进一步为靶向协同抑制肿瘤血管和淋巴管新生以及肿瘤治疗提供基础。

VEGF and bFGF are the most important proangiogenic factors in tumor angogenesis. The research results showed that VEGF and bFGF could synergistically promote angiogenesis, but there's no research reports about synergy inhibition of tumor angiogenesis. VEGF/bFGF polypeptide was constructed in our lab first, which could not only elicit high titer anti-VEGF and anti-bFGF antibodies in the body at the same time, but also competitively bind the receptors to inhibit tumor growth. The former research results demonstrated the function of VEGF/bFGF polypeptide in tumor inhibition. The further research work will be carried out in the functions of anti-tumor therapy, metastasis and related mechanism of VEGF/bFGF polypeptide, the immune response mechanism in vivo,to explore the related signalling pathway of tumor inhibition and anti-angiogenesis, clarify the related mechanism of anti-angogenesis and anti-lymphangiogenesis and the effects to overcome the resistance of monofactor anti-VEGF or anti-bFGF therapy. The results will provide the mechanism and theoretical support for the synergy inhibiton of tumor angiogenesis and tumor therapy.